Pandion Therapeutics, Inc. (PAND) has 16 open-market insider trades by 14 insiders since 2020. The most active filer is Daniel J. Becker, Director.
| Name | Title | Tier | Trades | Value | Last Trade |
|---|---|---|---|---|---|
| Daniel J. Becker | Dir | — | 3 | $19.9M | 2021-04-01 |
| Christopher Fuglesang | Dir10% Owner | — | 1 | $13.0M | 2021-04-01 |
| Glaxosmithkline PLC | Dir10% Owner | — | 1 | $6.5M | 2020-07-21 |
| Jill Carroll | Dir10% Owner | — | 1 | $6.5M | 2021-04-01 |
| Alan L. Crane | Dir10% Owner | — | 1 | $902K | 2021-04-01 |
| Mitchell Mutz | Dir10% Owner | — | 1 | $830K | 2020-07-21 |
| Rahul Kakkar | CEO | — | 1 | $252K | 2021-04-01 |
| Donald Frail | Dir | — | 1 | $180K | 2021-04-01 |
| John Sundy | Chief Medical Officer | — | 1 | $36K | 2021-04-01 |
| Vikas Goyal | — | — | 1 | $26K | 2021-04-01 |
| Insider | Title | Type | Value | Date |
|---|---|---|---|---|
| Daniel J. Becker | Director | Buy | $6.0M | 2020-11-19 |
| Daniel J. Becker | Director | Buy | $867K | 2020-11-17 |
| Polaris Entrepreneurs' Fund VIII, L.P. | 10% | Buy | $22K | 2020-07-21 |
| Jill Carroll | Director & 10% Owner | Buy | $6.5M | 2020-07-21 |
| Alan L. Crane | Director & 10% Owner | Buy | $902K | 2020-07-21 |
| Christopher Fuglesang | Director & 10% Owner | Buy | $13.0M |
Companies that share insiders with PAND, and sector peers with recent insider buying. Related by who files, not by how the stocks move.
| 2020-07-21 |
| Daniel J. Becker | Director & 10% Owner | Buy | $13.0M | 2020-07-21 |
| Rahul Kakkar | CEO | Buy | $252K | 2020-07-21 |
| Donald Frail | Director | Buy | $180K | 2020-07-21 |
| Vikas Goyal | — | Buy | $26K | 2020-07-21 |
| Eric D. Larson | President & Finance | Buy | $11K | 2020-07-21 |
| John Sundy | Chief Medical Officer | Buy | $36K | 2020-07-21 |
| Nancy Stagliano | Director | Buy | $18K | 2020-07-21 |
| Joanne L. Viney | — | Buy | $22K | 2020-07-21 |
| Mitchell Mutz | Director & 10% Owner | Buy | $830K | 2020-07-21 |